Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLITAIRE-ORAL: Oral Solithromycin vs Moxifloxacin in CABP
NCT01756339Phase 3Completed
- Sponsor
- Melinta Therapeutics
- Start
- Dec 2012
- Primary completion
- Oct 2014
- Modality
- RNA-Targeting Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of solithromycin in community-acquired bacterial pneumonia (CAP), sponsored by Melinta Therapeutics. Started Dec 2012; status: completed.
02
Drugs
solithromycin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT01756339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01756339.